Hormone therapy and GLP-1: questions about combining them

Clarify the purpose of each treatment

Hormone therapy is considered for particular menopause symptoms or other medical reasons. Weight treatment has its own indication. Ask separately for each: what benefit are we expecting, how will we review it and which difficulties should improve? Two treatments being used at the same time does not make them automatically incompatible or establish a particularly effective combination. Keeping their purposes clear makes follow-up more useful.

Why the route of administration matters

Some hormones are swallowed; others are delivered through the skin or by another route. The weight medicines concerned can delay stomach emptying. That raises a reasonable question about medicines swallowed alongside them. A theoretical possibility is not proof of reduced effectiveness. Ask your pharmacist and clinicians to check the products you actually use against their current information, including any recent changes in treatment.

What specialist guidance identifies as uncertain

The British Menopause Society highlights a lack of robust evidence about effects on oral progestogens and protection of the womb lining. This uncertainty proves neither universal safety nor a general failure of hormone therapy.

British guidance is not a universal dosing plan for the EU or Switzerland. Do not apply suggested adjustments yourself. Reviewing your complete regimen is more useful than adding hormones “just in case”. Using a patch also does not automatically settle every question about the other components of your treatment. You need an assessment of the whole combination.

Describe new bleeding clearly

Record when unexpected bleeding starts, how long it lasts, how heavy it is and any recent changes to either treatment. New or unexpected bleeding deserves gynaecological assessment; it proves neither an interaction nor that the situation is harmless. Bleeding after menopause also needs checking. Seek appropriate prompt medical help for substantial symptoms or feeling faint, instead of waiting to complete a diary.

A small study is not a prescribing decision

A retrospective semaglutide study in 106 postmenopausal women found different weight outcomes with and without hormone therapy. Only 16 used hormones. Without random allocation, the findings cannot establish an additional treatment effect.

Starting hormones solely to lose more weight would therefore be premature. Equally, an evidence gap is not a reason to stop prescribed treatment on your own. Ask about the established benefits, risks and monitoring options that are relevant to your circumstances, rather than aiming to reproduce an average from a headline.

Make responsibilities clear

A short shared record is often enough: product, route, purpose, responsible clinician and next review. Include whom to contact about persistent vomiting, diarrhoea or bleeding. A change made by one team should be known to the other. Ask for an understandable plan for questions; you do not need to invent dose spacing or replacement doses when no specific instruction has been given.